Holen Sie sich die Stockscreener-App
79.99
8.53%
6.29
Handel nachbörslich:
79.84
-0.15
-0.19%
Schlusskurs vom Vortag:
$73.70
Offen:
$75
24-Stunden-Volumen:
32,087
Relative Volume:
0.20
Marktkapitalisierung:
$85.62M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-85.10
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
-11.81%
1M Leistung:
-15.93%
6M Leistung:
-86.69%
1J Leistung:
-90.34%
1-Tages-Spanne:
$74.20
$80.88
1-Wochen-Bereich:
$72.87
$91.05
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Vergleichen Sie SPRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
79.99 | 78.89M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace
Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - MarketScreener
Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets
Spruce Biosciences (SPRB) price target increased by 55.76% to 213.69 - MSN
MSN Money - MSN
Spruce Biosciences assumed with a buy at HC Wainwright - MSN
Spruce Biosciences (NASDAQ:SPRB) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Equities Analysts Offer Predictions for SPRB FY2025 Earnings - MarketBeat
Spruce Biosciences initiated with an Outperform at Oppenheimer - Yahoo Finance
Oppenheimer Initiates Coverage on SPRB with "Outperform" Rating - GuruFocus
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Yahoo Finance
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength - TradingView — Track All Markets
Oppenheimer initiates coverage on Spruce Biosciences stock with Outperform rating - Investing.com Australia
Oppenheimer Initiates Coverage of Spruce Biosciences (SPRB) with Outperform Recommendation - Nasdaq
Revenue per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView — Track All Markets
Spruce Biosciences stock rating resumed at Buy by H.C. Wainwright - Investing.com Nigeria
HC Wainwright Reaffirms Buy Rating for Spruce Biosciences (NASDAQ:SPRB) - MarketBeat
SPRB Stock: HC Wainwright & Co. Initiates Coverage with Buy Rati - GuruFocus
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P TMI Index - marketscreener.com
[Form 4] SPRUCE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Spruce Biosciences CEO reports RSU vesting and option repricing | SPRB SEC FilingForm 4 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail
Spruce Biosciences (SPRB) adjusts director option exercise prices to $104.13 - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) reprices stock options after reverse split - Stock Titan
Spruce Biosciences (SPRB) details one-time executive stock option repricing - Stock Titan
Spruce Biosciences (SPRB) discloses CEO stock option repricing to $104.13 - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) details one-time director option repricing - Stock Titan
Spruce Biosciences (SPRB) details 800 stock options repriced for director - Stock Titan
Spruce Biosciences (SPRB) director receives 3,400 options at $88.41 - Stock Titan
[Form 3] SPRUCE BIOSCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directo - PharmiWeb.com
Spruce Biosciences appoints Keli Walbert to board of directors By Investing.com - Investing.com Australia
Spruce Biosciences appoints Keli Walbert to board of directors - marketscreener.com
Spruce Biosciences Appoints Keli Walbert To Board Of Directors - TradingView — Track All Markets
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors - Investing News Network
Spruce Biosciences (NASDAQ: SPRB) names rare-disease veteran Keli Walbert to board - Stock Titan
Spruce Biosciences (SPRB) adds Keli Walbert to board with cash and equity pay - Stock Titan
CEO Szwarcberg Acquires 3,524 Of Spruce Biosciences Inc [SPRB] - TradingView — Track All Markets
[8-K] SPRUCE BIOSCIENCES, INC. Reports Material Event | SPRB SEC FilingForm 8-K - Stock Titan
Spruce Biosciences (SPRB) insider RSU vesting and tax share withholding - Stock Titan
Stock Ratings | Guggenheim maintained its "buy" recommendation on Cybin Inc. Common Shares (CYBN) and raised its price target to $48 from $39, representing a potential upside of 378.12%. - Sahm
Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spruce Biosciences Inc-Aktie (SPRB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):